Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug 2;18(1):82.
doi: 10.1186/s12881-017-0440-5.

A systematic review of genetic mutations in pulmonary arterial hypertension

Affiliations

A systematic review of genetic mutations in pulmonary arterial hypertension

Gerardo Garcia-Rivas et al. BMC Med Genet. .

Abstract

Background: Pulmonary arterial hypertension (PAH) is a group of vascular diseases that produce right ventricular dysfunction, heart failure syndrome, and death. Although the majority of patients appear idiopathic, accumulated research work combined with current sequencing technology show that many gene variants could be an important component of the disease. However, current guidelines, clinical practices, and available gene panels focus the diagnosis of PAH on a relatively low number of genes and variants associated with the bone morphogenic proteins and transforming Growth Factor-β pathways, such as the BMPR2, ACVRL1, CAV1, ENG, and SMAD9.

Methods: To provide an expanded view of the genes and variants associated with PAH, we performed a systematic literature review. Facilitated by a web tool, we classified, curated, and annotated most of the genes and PubMed abstracts related to PAH, in which many of the mutations and variants were not annotated in public databases such as ClinVar from NCBI. The gene list generated was compared with other available tests.

Results: Our results reveal that there is genetic evidence for at least 30 genes, of which 21 genes shown specific mutations. Most of the genes are not covered by current available genetic panels. Many of these variants were not annotated in the ClinVar database and a mapping of these mutations suggest that next generation sequencing is needed to cover all mutations found in PAH or related diseases. A pathway analysis of these genes indicated that, in addition to the BMP and TGFβ pathways, there was connections with the nitric oxide, prostaglandin, and calcium homeostasis signalling, which may be important components in PAH.

Conclusion: Our systematic review proposes an expanded gene panel for more accurate characterization of the genetic incidence and risk in PAH. Their usage would increase the knowledge of PAH in terms of genetic counseling, early diagnosis, and potential prognosis of the disease.

Keywords: Genetic panel; Germ-line mutation; Heterozygote detection; Systematic review.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The names of the companies offering the available gene panels were not included to avoid misinterpretations regarding conflicts of interest. The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
A schematic overview of the systematic review
Fig. 2
Fig. 2
Results of the curation process from abstracts to genes
Fig. 3
Fig. 3
Mutations reported and curated from the 21 genes having evidences of mutations. Only exons are shown and numbered except in cases of mutations upstream of the first exon. Color figure can be viewed in the online issue
Fig. 4
Fig. 4
Functional analysis of the genes found genetically altered in PAH. a Pathways and comorbilities. b Gene ontology terms. Only the genes with annotations in these terms are included in the mapping. Color figure can be viewed in the online issue

References

    1. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351:1655–1665. doi: 10.1056/NEJMra035488. - DOI - PubMed
    1. Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67–119. doi: 10.1093/eurheartj/ehv317. - DOI - PubMed
    1. Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-year outcomes of patients enrolled in the REVEAL registry. Chest. 2015;148:1043–1054. doi: 10.1378/chest.15-0300. - DOI - PubMed
    1. Lau EMT, Humbert M, Celermajer DS. Early detection of pulmonary arterial hypertension. Nat Rev Cardiol. 2015;12:143–155. doi: 10.1038/nrcardio.2014.191. - DOI - PubMed
    1. Soubrier F, Chung WK, Machado R, Grünig E, Aldred M, Geraci M, et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol. 2013;62:D13–D21. doi: 10.1016/j.jacc.2013.10.035. - DOI - PubMed

Publication types

MeSH terms

Substances